INFUSE-AMI: Intracoronary Abciximab in STEMI Patients

Volume 20 - Issue 5 - May 2012
Posted on: 5/2/12
0 Comments
3697 reads

Start Page:

End page:

Author(s):

Cath Lab Digest talks with Gregg W. Stone, MD, FACC, FSCAI,
Professor of Medicine, Columbia University, Director of
Cardiovascular Research and Education, Center for Interventional Vascular Therapy, Columbia Medical Center and the Cardiovascular Research Foundation, New York, New York.

The results clearly demonstrate that in high-risk patients presenting early in the course of a large evolving anterior MI undergoing primary PCI with bivalirudin anticoagulation, bolus intracoronary abciximab delivered to the infarct lesion site via the ClearWay Rx Infusion Catheter results in a significant reduction in infarct size at 30 days. A randomized trial powered for clinical and safety endpoints is thus warranted to determine the role of local abciximab delivery in STEMI. In contrast, manual thrombus aspiration did not reduce infarct size. The final word on aspiration in STEMI awaits the ongoing results from two large randomized trials ongoing in Sweden and Canada.

Dr. Stone can be contacted at gs2184@columbia.edu.

Disclosure: Dr. Stone reports he is a consultant to Abbott Vascular, Boston Scientific, Medtronic, Atrium, BMS-Sanofi, Merck, Janssen, Eli Lilly, Daiichi Sankyo, The Medicines Company, and Astra Zeneca.